Background: The maternal serum alpha-fetoprotein test (MSAFP) was developed to screen
for neural tube defects. Little is known about the adoption of the MSAFP test. This study …

Most maternal serum alpha-fetoprotein (MSAFP) screening programs are set up with the
goal of prenatal detection of fetal neural tube defects. It is also commonly accepted that …

Methods: The population surveyed was the Collaborative Ambulatory Research Network, a
voluntary subset of 550 ACOG fellows from 130 practices participating in data collection …

Based upon previously published reports, the benefits and risks of screening a hypothetical
population of 10,000 women are analyzed, and the cost benefit of maternal serum a …

ATERNAL SERUM a-fetoprotein (MSAFP) screening at 15 to 20 weeks of pregnancy can
detect approximately 80% of neural tube defects (NTDs), 20% of Down syndrome cases …

The alpha-fetoprotein screening test for neural tube defects can provide specific information
on the condition of an unborn fetus and can offer reassurance to families at increased risk for …

Maternal serum alpha-fetoprotein (MSAFP) screening of all pregnant women between 15
and 20 weeks gestational age is generally recognized as a standard of care in current …

Maternal serum α-fetoprotein (MSAFP) screening was offered in a private suburban practice
to 21,000 nondiabetic and 442 diabetic women with apparently normal pregnancies. Using …

We investigated the knowledge of pregnant women participating in a maternal serum
alphafetoprotein (MSAFP) screening program for the detection of neural tube defects (NTDs) …

Objectives. We questioned whether race-specific databases for maternal serum
alphafetoprotein (MSAFP) screening should be added to those already available for African …